CC-99712 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).
SparkCures ID | 358 |
---|---|
Developed By | Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb |
Generic Name | CC-99712 |
Treatment Classifications | |
Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.